ECE2022 Eposter Presentations Reproductive and Developmental Endocrinology (93 abstracts)
Gender affirming hormonal treatment in Danish transgender persons. A nationwide register-based study
Dorte Glintborg 1 , Katrine Hass Rubin 1 , Simon Bang Kristensen 1 , Øjvind Lidegaard 2 , Guy T’Sjoen 3 , Malene Hilden 2 & Marianne Skovsager Andersen 1
1Odense University Hospital, Odense, Denmark; 2Copenhagen University, København, Denmark; 3Ghent University Hospital, Gent, Belgium
Background: Gender affirming hormonal treatment (GAHT) is for many a cornerstone of transgender care. National data regarding use of hormonal treatment by transgender persons are limited.
Aim: To assess use of GAHT in transgender persons.
Design: National register-based cohort study in Danish transgender persons followed from 2000 until 2018. The main outcome measure was redemption of GAHT. Persons with an ICD-10 diagnosis code of “gender identity disorder” (CGI-cohort) and persons with legal sex change but without diagnosis (CPR-cohort) were included. In the CGI-cohort, transgender women were defined by prescription of estrogen and/or antiandrogens and transgender men were defined by prescription of testosterone after study inclusion. Discontinuation of GAHT was defined as no redemption of GAHT ≥ 13 months or shift from feminizing to masculinizing hormone treatment, or vice versa.
Results: The cohort included 2770 transgender persons (n=1700, CGI-cohort and n = 1070, CPR-cohort). The median age (interquartile range) at study inclusion was 26.0 (17.3) years for persons assigned male at birth (n=1437) and 22.5 (10.4) years for persons assigned female at birth (n= 1333). In the CGI-cohort, the redemption rate for GAHT in transgender women increased from 4.0 (95% CI: [3.1; 5.2]) events per 100 person in year 2000-2005 to 20.5 [17.7; 23.6] between 2014 -2018. In transgender men, the event rate of GAHT increased from 4.2 [2.8; 6.2] to 18.9 [16.4; 21.7]. The rate of discontinuation of GAHT was 0.06 (95% CI 0.048; 0.071) per person year.
Conclusions: The event rate of GAHT increased during 2000-2018. Our data suggested high adherence to GAHT.
Article tools
My recent searches
My recently viewed abstracts
Authors
Endocrine Abstracts
ISSN 1470-3947 (print) | ISSN 1479-6848 (online)
© Bioscientifica 2024 |
Privacy policy |
Cookie settings
BiosciAbstracts
Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.
Find out more